Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US5886035 | AKORN | Difluoroprostaglandin derivatives and their use |
Dec, 2022
(3 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10864159 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(6 years from now) | |
US9999593 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(6 years from now) |
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
8
Japan
6
European Union
5
Korea, Republic of
4
Denmark
4
Slovenia
4
United States
4
Croatia
4
Portugal
4
Spain
4
Poland
3
Lithuania
3
Hungary
2
Argentina
2
Cyprus
2
Canada
1
Mexico
1
Australia
1
Jordan
1
Singapore
1
Brazil
1
Malaysia
1
Taiwan, Province of China
1
China
1
Georgia
1
Ukraine
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic